Anxiety and depression in patients who receive anti-VEGF treatment and the usability and feasibility of e-mental health support: the E-PsEYE pilot study.
Hilde P A van der AaGer Hmb van RensFrank D VerbraakMachteld BosschaHannie C ComijsRuth Marie Antoinette van NispenPublished in: Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) (2021)
Mental health problems are prevalent in patients who receive anti-VEGF treatment. Healthcare providers should recognise these problems and related factors in order to refer patients to appropriate care in a timely manner. Outcomes on the usability and feasibility of E-PsEYE are promising as a prelude to performing a randomised controlled trial, which will shed more light on its (cost-)effectiveness.
Keyphrases
- mental health
- healthcare
- end stage renal disease
- vascular endothelial growth factor
- endothelial cells
- mental illness
- chronic kidney disease
- ejection fraction
- health information
- type diabetes
- palliative care
- electronic health record
- metabolic syndrome
- combination therapy
- prognostic factors
- quality improvement
- peritoneal dialysis
- insulin resistance